These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12616671)

  • 41. Comparative bioavailability of two risperidone orodispersible tablet products after single dose administration.
    Tassaneeyakul W; Kumar S; Gaysonsiri D; Kaewkamson T; Khuroo A; Tangsucharit P; Phunikhom K; Vannaprasaht S; Kanjanawart S; Rao Thudi N; Jain R; Reyar S; Monif T
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):614-20. PubMed ID: 20860915
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Single dose pharmacokinetics of the novel transdermal donepezil patch in healthy volunteers.
    Kim YH; Choi HY; Lim HS; Lee SH; Jeon HS; Hong D; Kim SS; Choi YK; Bae KS
    Drug Des Devel Ther; 2015; 9():1419-26. PubMed ID: 25792802
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Genotyping as a Key Element of Sample Size Optimization in Bioequivalence of Risperidone Tablets.
    Chen Y; Deng Y; Yan M; Hou Z; Li Y; Zhang B; Cai H
    Eur J Drug Metab Pharmacokinet; 2018 Aug; 43(4):431-439. PubMed ID: 29404931
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
    Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
    Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia.
    Eerdekens M; Van Hove I; Remmerie B; Mannaert E
    Schizophr Res; 2004 Sep; 70(1):91-100. PubMed ID: 15246468
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pisa syndrome due to donepezil: pharmacokinetic interactions to blame?
    Pollock D; Cunningham E; McGuinness B; Passmore AP
    Age Ageing; 2017 May; 46(3):529-530. PubMed ID: 28104598
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical profile of donepezil in the treatment of Alzheimer's disease.
    Doody RS
    Gerontology; 1999; 45 Suppl 1():23-32. PubMed ID: 9876215
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A fixed-dose combination of memantine extended-release and donepezil in the treatment of moderate-to-severe Alzheimer's disease.
    Deardorff WJ; Grossberg GT
    Drug Des Devel Ther; 2016; 10():3267-3279. PubMed ID: 27757016
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Donepezil for vascular cognitive impairment.
    Malouf R; Birks J
    Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Concentration of Donepezil in the Cerebrospinal Fluid of AD Patients: Evaluation of Dosage Sufficiency in Standard Treatment Strategy.
    Valis M; Masopust J; Vysata O; Hort J; Dolezal R; Tomek J; Misik J; Kuca K; Karasova JZ
    Neurotox Res; 2017 Jan; 31(1):162-168. PubMed ID: 27718143
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Higher-dose (23 mg/day) donepezil formulation for the treatment of patients with moderate-to-severe Alzheimer's disease.
    Christensen DD
    Postgrad Med; 2012 Nov; 124(6):110-6. PubMed ID: 23322144
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
    Burns A; Gauthier S; Perdomo C
    Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The safety and tolerability of donepezil in patients with Alzheimer's disease.
    Jackson S; Ham RJ; Wilkinson D
    Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):1-8. PubMed ID: 15496217
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and Pharmacokinetics of HTL0018318, a Novel M
    Bakker C; van der Aart J; Labots G; Liptrot J; Cross DM; Klaassen ES; Dickinson S; Tasker T; Groeneveld GJ
    Drugs R D; 2021 Sep; 21(3):295-304. PubMed ID: 34164794
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Combination of risperidone and donepezil in Lewy body dementia.
    Geizer M; Ancill RJ
    Can J Psychiatry; 1998 May; 43(4):421-2. PubMed ID: 9598283
    [No Abstract]   [Full Text] [Related]  

  • 56. Memantine and donepezil: a fixed drug combination for the treatment of moderate to severe Alzheimer's dementia.
    Owen RT
    Drugs Today (Barc); 2016 Apr; 52(4):239-48. PubMed ID: 27252988
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
    Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
    J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Assessing pharmacokinetic interactions between the sodium glucose cotransporter 2 inhibitor empagliflozin and hydrochlorothiazide or torasemide in patients with type 2 diabetes mellitus: a randomized, open-label, crossover study.
    Heise T; Mattheus M; Woerle HJ; Broedl UC; Macha S
    Clin Ther; 2015 Apr; 37(4):793-803. PubMed ID: 25636696
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pharmacokinetic and pharmacodynamic evaluation of donepezil for the treatment of Alzheimer's disease.
    Prvulovic D; Schneider B
    Expert Opin Drug Metab Toxicol; 2014 Jul; 10(7):1039-50. PubMed ID: 24785550
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Extrapyramidal side effects in a patient treated with risperidone plus donepezil.
    Magnuson TM; Keller BK; Burke WJ
    Am J Psychiatry; 1998 Oct; 155(10):1458-9. PubMed ID: 9766783
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.